What Pharma Firms Should Be Doing Now to Prepare for a ‘No Deal' Brexit

Executive Summary As Brexit uncertainty continues and a “no-deal” scenario remains a possibility, pharmaceutical companies need to be looking at issues such as the renegotiation of supplier contracts, the transfer of key regulatory roles, and the mapping of trade flows, says EFPIA’s president, Stefan Oschmann. Meanwhile, industry and healthcare...

Executive Summary

As Brexit uncertainty continues and a “no-deal” scenario remains a possibility, pharmaceutical companies need to be looking at issues such as the renegotiation of supplier contracts, the transfer of key regulatory roles, and the mapping of trade flows, says EFPIA’s president, Stefan Oschmann. Meanwhile, industry and healthcare organizations have drawn up a list of “crucial unanswered questions” that they say the Brexit negotiators must address.

Brexit
Source: pink.pharmamedtechbi.com